Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet 2026

View at publisher
Authors: Megan E B Clowse, David A Isenberg, Joan T Merrill, Thomas Dörner, Michelle Petri, Edward M Vital, Eric F Morand, Zahi Touma, Anca D Askanase, Yiannis Ioannou, Stephen Brookes, Janine Gaiha-Rohrbach
+6 more E Dietlind Koch, Nour Zibian, Christophe Martin, Teri Jimenez, Annette Nelde, Christian Stach
DOI: 10.1016/s0140-6736(26)00691-4
Cited by: 4
References: 27

Fields of Study & Subjects

Systemic Lupus Erythematosus Research T-cell and B-cell Immunology Multiple Sclerosis Research Studies

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10545
Pages
2291–2304
Publication date
29 May 2026
Language
EN